A new study has shown that AI avatar–based digital patient engagement prior to in-person radiation treatment consultations may enable patients to feel more knowledgeable and less stressed than patients who did not engage with an AI avatar, according to findings presented during the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026; Abstract 4187).

Fifteen-year results from the phase III ASCENDE-RT trial in patients with intermediate- and high-risk localized prostate cancer receiving androgen-deprivation therapy (ADT) and pelvic external-beam radiotherapy (EBRT) show no significant overall survival advantage with a prostate brachytherapy boost vs an EBRT boost, with a signal toward improved prostate cancer–specific survival that was sensitive to challenges in determining cause of death, according to findings presented by Scott Tyldesley, MD, FRCPC, of BC Cancer Vancouver, at the 2026 ASCO Genitourinary (GU) Cancers Symposium.¹

On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD), as determined by an FDA-authorized test.

Final overall survival results from the phase III ROSELLA trial showed a statistically and clinically significant survival benefit with the selective glucocorticoid receptor antagonist relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer. Median overall survival was 16.0 months with the combination compared with 11.9 months with nab-paclitaxel monotherapy, yielding a hazard ratio (HR) of 0.65 and a 35% reduction in the risk of death.